Growth Hormone Secretagogue
GHRP-6
BioHarmony verdict
Neutral
GHRP-6 is a synthetic peptide that activates the ghrelin receptor to release a pulse of your own growth hormone. It is historically pivotal but the least selective common option, with the heaviest appetite, cortisol, and prolactin effects, and no human outcome trial for body composition, per Cabrales 2013 and Locke 1995.
Read full reportWhat is GHRP-6?
GHRP-6, short for Growth Hormone Releasing Peptide-6, is a lab-made six-amino-acid peptide that nudges your own pituitary to release a short pulse of growth hormone. It does this by activating the ghrelin receptor, the same receptor your stomach hormone ghrelin uses, which sits on the pituitary and in the brain. It is one of the original peptides in this family, and that history is its biggest claim to importance. GHRP-6 was the research tool scientists used to clone that receptor, per Howard 1996, and that work led them straight to the discovery of ghrelin itself, per Kojima 1999. In other words, a synthetic peptide reverse-engineered an entire hormone system.
From the BioHarmony report, reviewed 2026-09-08.
How it is thought to work
Agonist at the growth-hormone secretagogue receptor (the ghrelin receptor) on the pituitary and hypothalamus
Safety watch-outs
- Hunger so strong it derails your eating plan: reduce dose or switch to a more selective option.
- Rising fasting glucose or new insulin-resistance signs: stop and consult a clinician, especially with diabetes.
- Any active or suspected cancer: do not use, since growth-hormone and IGF-1 stimulation is contraindicated.
- Signs of low mood, low libido, or breast tenderness: possible cortisol or prolactin effect, reduce dose or stop.
Full risk profile in the BioHarmony report.
Dosing as published
No approved-label or study protocol is recorded for GHRP-6 yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (1)
Attributed viewpoints, separate from primary research.
- International Peptide Society 2018 Compound CurriculumDr. William Seeds · 2018-07-20
Trust & sourcing
FDA places GHRP-6 in 503B Category 2 and identifies immunogenicity concerns plus limited safety data involving cortisol and blood-glucose effects.
Primary sources
- Certain bulk drug substances for use in compounding that may present significant safety risksU.S. Food and Drug Administration · 2026-04-22
Related peptides for recovery & tissue repair
Free guide
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.